Details of the Metabolic Reaction (MR)

General Information of This Metabolic Reaction (MR) (ID: MR001437)
Formula
SVG example
Dealkylation
Reactant Lenvatinib mesylate Product Lenvatinib mesylate metabolite M2
Reactant Info Product Info
Metabolic Type Oxidation - Dealkylation
Other MR(s) Related to The Reactant of This MR
Other MR(s) That Metabolize The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR001442 Lenvatinib mesylate . Unclear Lenvatinib mesylate [1]
MR001439 Lenvatinib mesylate Lenvatinib mesylate metabolite M1 Oxidation - Dealkylation Lenvatinib mesylate [2]
MR001440 Lenvatinib mesylate Lenvatinib mesylate metabolite M3 Oxidation - N-Oxidation Lenvatinib mesylate [2]
MR001441 Lenvatinib mesylate Lenvatinib mesylate metabolite M30 Hydrolysis - Hydrolysis Lenvatinib mesylate [2]
MR001438 Lenvatinib mesylate Lenvatinib mesylate metabolite M32 Hydrolysis - Hydrolysis Lenvatinib mesylate [2]
Other MR(s) Related to The Product of This MR
Other MR(s) That Produce The Product of This MR
MR ID Reactant Product MR Type Related Drug REF
MR010933 Lenvatinib O-demethyl Lenvatinib Unclear - Unclear Lenvatinib [3]
Other MR(s) That Metabolize The Produtc of This MR
MR ID Reactant Product MR Type Related Drug REF
MR001435 Lenvatinib mesylate metabolite M2 Lenvatinib mesylate metabolite H Conjugation - Glucuronidation Lenvatinib mesylate [2]
MR001434 Lenvatinib mesylate metabolite M2 Lenvatinib mesylate metabolite M2' Oxidation - Oxidation Lenvatinib mesylate [2]
References
1 Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer. Sci Rep. 2019 Apr 1;9(1):5404.
2 Metabolite profiling of the multiple tyrosine kinase inhibitor lenvatinib: a cross-species comparison Invest New Drugs. 2016 Jun;34(3):300-18. doi: 10.1007/s10637-016-0342-y.
3 The impact of individual human cytochrome P450 enzymes on oxidative metabolism of anticancer drug lenvatinib

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.